ArticleApplied immunohistochemistry & molecular morphology : AIMM2025
TAGLN2-mediated Actin Cytoskeleton Stabilization Promotes Proliferation and Metastasis of Ovarian Carcinoma.
Article in Applied immunohistochemistry & molecular morphology : AIMM, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An Anoikis-Related Gene Signature Associated With Stromal Remodeling and Clinical Outcome in Gastric Cancer.Chemical biology & drug design · 2026Article
- Hsa_circ_PCNT sponges hsa-miR-133b to promote SHH medulloblastoma via TAGLN2.Cellular and molecular life sciences : CMLS · 2026Article
- CKAP2L promotes endometrial cancer progression by suppressing AKT ubiquitination and activating the PI3K/AKT signaling pathway.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Transgelin-2 (TAGLN2) is an actin-binding protein associated with tumor progression, particularly in gastric and brain tumors. However, its role in ovarian cancer metastasis is still not fully understood. This study investigated the role of TAGLN2 and its potential mechanism in ovarian cancer metastasis. TAGLN2 expression in ovarian cancer and normal tissues was assessed using Oncomine, Human Protein Atlas (HPA), and immunocytochemistry (IHC). Skov3 cells with TAGLN2 knockdown (transient knockdown of TAGLN2 of homo TAGLN2 was performed using specific small interfering RNAs), and Skov3 cells transfected with scrambled siRNAs (negative control group) were subjected to colony formation and wound healing assays to assess cell proliferation and migration in vitro. RT-PCR and western blot were used to assess TAGLN2 mRNA and protein expression; immunofluorescence staining was used to investigate the TAGLN2 impact on the cytoskeletal organization. Elevated TAGLN2 levels were observed in ovarian cancer compared with normal tissues, which was confirmed by IHC of a tissue microarray containing 65 ovarian tumor samples. TAGLN2 knockdown reduced cell proliferation and migration in vitro. Also, TAGLN2 was found to co-localize with F-actin; the knockdown of TAGLN2 impaired cytoskeletal organization, emphasizing its influence on cellular structures. In summary, TAGLN2, highly expressed in ovarian cancer, promotes migration and proliferation through cytoskeletal reorganization; thus, it may be a new therapeutic target for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.